Anti-interleukin-5 (IL-5) biologic therapy in eosinophilia — the monoclonal antibodies targeting IL-5 or its receptor (IL-5R) to reduce eosinophil production, maturation, and survival in hypereosinophilic syndromes, severe eosinophilic asthma, and eosinophilic granulomatosis with polyangiitis — represents the fastest-growing drug class in the global eosinophilia therapeutic market, with the Eosinophilia Therapeutic Market reflecting anti-IL-5 biologic advancement as the premium growth commercial driver.
The eosinophilic disease spectrum expansion — the increasing recognition of eosinophils as central effector cells in asthma, EGPA, hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE), and chronic rhinosinusitis with nasal polyps creating the multi-indication demand foundation. The market valued at USD 316.7 million across the top 7 markets in 2025 and projected to reach USD 523.9 million by 2036 at a 4.54% CAGR, with the broader eosinophilic asthma treatment market alone reaching USD 1.15 billion in 2024 and growing to USD 1.81 billion by 2033. The biologics segment expected to lead with 44.6% of drug class demand in 2026, with mepolizumab, reslizumab, and benralizumab demonstrating 50%+ exacerbation reduction in eosinophilic asthma.
Mepolizumab HES approval and steroid-sparing validation — the FDA approval of mepolizumab (Nucala) for hypereosinophilic syndrome in September 2020 as the first targeted therapy for HES, and the subsequent long-term safety and efficacy confirmation in open-label extension studies establishing the clinical standard. The mepolizumab demonstrated as safe and effective as a steroid-sparing agent in HES including lymphocytic variant HES, with monthly subcutaneous dosing improving patient convenience. The compassionate use clinical protocol expanding access for life-threatening HES refractory to standard therapies.
Dupilumab and IL-4/IL-13 pathway expansion — the dupilumab (Dupixent) approval for eosinophilic esophagitis in 2022 as the first biologic for EoE, and the AstraZeneca Exdensur (depemokimab) launch in January 2026 after AI-guided patient stratification confirmed benefit in severe eosinophilic asthma. The tezepelumab (Tezspire) acting upstream in the inflammatory cascade and the emerging TSLP inhibitors expanding the mechanistic diversity beyond IL-5 targeting. The Areteia Therapeutics dexpramipexole positive Phase III EXHALE-4 results in September 2025 offering an oral add-on alternative.
Do you think oral small-molecule eosinophil-targeting therapies like dexpramipexole will eventually replace injectable biologics for eosinophilic conditions, or will the established efficacy, dosing convenience, and reimbursement infrastructure of anti-IL-5 antibodies maintain their market leadership?
FAQ
What are the leading eosinophilia therapeutic drugs and their mechanisms? Leading eosinophilia therapeutic drugs: Mepolizumab (Nucala — GSK, anti-IL-5, FDA approved HES 2020, eosinophilic asthma, EGPA, monthly SC, steroid-sparing); Reslizumab (Cinqair — Teva, anti-IL-5, IV, eosinophilic asthma, 15+ years, adults); Benralizumab (Fasenra — AstraZeneca, anti-IL-5R, enhanced ADCC, eosinophilic asthma, COPD, every 8 weeks); Dupilumab (Dupixent — Sanofi/Regeneron, anti-IL-4Rα, blocks IL-4/IL-13, EoE, asthma, atopic dermatitis, biweekly SC); Depemokimab (Exdensur — AstraZeneca, anti-IL-5, extended dosing, AI-stratified, January 2026 launch); Tezepelumab (Tezspire — AstraZeneca/Amgen, anti-TSLP, upstream, severe asthma, eosinophil-independent); Dexpramipexole (Areteia, oral, eosinophil-lowering, Phase III positive EXHALE-4, September 2025); Corticosteroids (prednisone, methylprednisolone — first-line HES, broad immunosuppression, high relapse, long-term toxicity); Imatinib (Gleevec — TKI, FIP1L1-PDGFRA+ HES, molecular remission, first-line for this subset); Hydroxyurea, interferon-α (second-line HES, ~30% response); Key mechanisms: Anti-IL-5 (blocks eosinophil production/survival); Anti-IL-5R (blocks receptor, enhanced antibody-dependent cellular cytotoxicity); Anti-IL-4Rα (blocks IL-4/IL-13, Th2 inflammation); Anti-TSLP (upstream, broad anti-inflammatory); Oral eosinophil-lowering (dexpramipexole, mechanism under investigation).
What is the market size and competitive landscape for eosinophilia therapeutics? Eosinophilia therapeutic market economics: Eosinophilia market (7MM): USD 316.7 million (2025) to USD 523.9 million (2036) at 4.54% CAGR (IMARC); Eosinophilic asthma treatment: USD 1.15 billion (2024) to USD 1.81 billion (2033) at 5.16% CAGR; Eosinophilic asthma treatment (BRI): USD 70.27 billion (2026) to USD 1,354.55 billion (2035) at 38.8% CAGR (broader definition); EGPA treatment: USD 201.5 million (2026) to USD 322.1 million (2036) at 4.8% CAGR; Eosinophilic esophagitis (7MM): ~USD 650 million U.S. (2025) to USD 3.54 billion (2036); Segments: Biologics (44.6% share, 2026, fastest-growing); Corticosteroids (largest current, declining); Immunosuppressants; Monoclonal antibodies (anti-IL-5, anti-IL-5R, anti-IL-4R); Small molecules (emerging, oral); Regional: North America (largest, U.S. dominant, advanced diagnosis); Europe (Germany, UK, NICE/HAS assessments); Asia-Pacific (fastest-growing, Japan 4.8% CAGR, South Korea 4.7%); Key players: GSK (mepolizumab, Nucala, market pioneer); AstraZeneca (benralizumab, Fasenra, tezepelumab, depemokimab); Sanofi/Regeneron (dupilumab, Dupixent); Teva (reslizumab, Cinqair); Novartis (pipeline); Roche/Genentech (mepolizumab partnership); Areteia Therapeutics (dexpramipexole, oral); Bristol-Myers Squibb (cendakimab, pipeline); Allakos (lirentelimab, pipeline); Pricing: Mepolizumab: $30,000-40,000 annually; Benralizumab: $35,000-45,000; Dupilumab: $35,000-50,000; Tezepelumab: $35,000-45,000; Corticosteroids: $100-500 annually; Imatinib (HES): $5,000-10,000; Growth drivers: Eosinophilic disease recognition, biologic approvals, steroid-sparing need, asthma-COPD overlap, EoE prevalence, EGPA diagnosis, rare disease incentives, AI-guided precision medicine.
#EosinophiliaTherapeutic #AntiIL5 #Mepolizumab #Benralizumab #EosinophilicAsthma #HypereosinophilicSyndrome #Biologics